Drug Profile

Cosiporfin sodium - Shanghai Guangsheng Biopharmaceutical

Alternative Names: Heme porphyrin sodium - Shanghai Guangsheng Biopharmaceutical

Latest Information Update: 18 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

17 Feb 2026 Shanghai Guangsheng Pharmaceutical has patent protection for ether-linked porphyrin dimer salt and preparation method thereof in China
17 Feb 2026 Shanghai Guangsheng Pharmaceutical has patents pending for combination therapy of photodynamic therapy and immune checkpoint inhibitors in China and worldwide
04 Feb 2026 Phase-II clinical trials in Cholangiocarcinoma (Late-stage disease, Combination therapy, Metastatic disease, Recurrent) in China (IV) (NCT07398339)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com